YOLFTbeta
Mediwound Ltd

Mediwound Ltd

MDWD · NASDAQ · Healthcare / Biotechnology

12.90USD-0.07 (-0.54%)

Price History

Full chart

Market Stats

Previous Close12.97
Open13.00
Day Range12.77 – 13.23
52-Week Range12.52 – 20.03
Volume189.68K
Market Cap178.68M
P/E (TTM)0.00
Forward P/E34.97
EPS-2.16
Dividend Yield0.00%
Beta0.14
50-Day Avg13.69
200-Day Avg15.96

About

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Ofer Gonen B.Sc.
  • Employees121
  • Headquarters42 Hayarkon Street, Yavne, Israel, 8122745, USA
  • Websitehttps://www.mediwound.com

Leadership

  • Mr. Ofer Gonen B.Sc.Chief Executive Officer · b. 1973
  • Ms. Hani LuxenburgChief Financial Officer · b. 1974
  • Dr. Shmulik Hess Ph.D.COO & Chief Commercial Officer · b. 1974
  • Mr. Yaron Meyer Adv.Executive VP, General Counsel & Corporate Secretary · b. 1979
  • Dr. Ety Klinger MBA, Ph.D.Chief Medical Officer · b. 1962
  • Dr. Liron GalVice President of Manufacturing Science & Technology
  • Mr. Barry J. WolfensonExecutive Vice President of Strategy & Corporate Development · b. 1967
  • Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc.Senior Vice President of Global Medical Affairs · b. 1951

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--0259.00K601.00K1.56M2.50M3.40M31.79M21.76M23.76M26.50M18.69M20.22M16.96M
Growth (%)----+132.05%+159.23%+60.21%+36.26%+834.70%-31.54%+9.19%+11.50%-29.48%+8.22%-16.14%
Cost of Revenue-268.00K335.00K2.79M2.52M2.16M1.58M2.09M11.85M14.22M14.99M13.33M15.11M17.59M13.71M
Gross Profit--268.00K-335.00K-2.53M-1.92M-600.00K918.00K1.31M19.94M7.54M8.77M13.16M3.58M2.63M3.25M
Gross Margin----975.29%-319.13%-38.51%36.78%38.61%62.73%34.67%36.91%49.69%19.15%13.03%19.19%
Operating Expense-2.46M7.25M18.90M19.31M19.55M14.61M5.27M15.45M16.39M19.99M20.83M19.08M22.02M28.53M
Operating Income-4.29M-2.73M-7.58M-21.43M-21.23M-20.16M-13.69M-3.96M4.49M-8.84M-11.22M-7.66M-15.50M-19.38M-25.28M
Operating Margin----8272.97%-3531.95%-1293.65%-548.36%-116.44%14.13%-40.62%-47.22%-28.91%-82.96%-95.85%-149.06%
EBITDA-4.10M12.25M-6.50M-17.59M-20.32M-17.45M-13.14M-4.20M4.14M-7.35M-11.38M-18.25M-4.80M-27.93M-21.47M
EBITDA Margin----6791.89%-3381.70%-1119.96%-526.40%-123.38%13.02%-33.79%-47.90%-68.87%-25.69%-138.11%-126.60%
Net Income-6.17M10.94M-15.35M-18.88M-22.09M-18.89M-22.15M-1.06M4.96M-9.20M-13.55M-19.60M-6.72M-30.22M-23.88M
Net Income Margin----7287.64%-3675.21%-1212.13%-887.38%-31.08%15.59%-42.26%-57.03%-73.97%-35.94%-149.46%-140.80%
R&D3.02M1.32M3.36M5.35M6.02M7.07M5.46M4.07M4.97M7.70M10.26M10.18M7.47M8.88M14.32M
R&D as % of Total Revenue---2065.25%1001.83%453.66%218.83%119.73%15.63%35.37%43.16%38.42%39.96%43.90%84.44%
Interest Expense591.00K673.00K1.67M57.00K444.00K847.00K827.00K892.00K207.00K200.00K167.00K162.00K335.00K561.00K663.00K
Interest Expense % of Total Revenue---22.01%73.88%54.36%33.13%26.23%0.65%0.92%0.70%0.61%1.79%2.77%3.91%

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-25.44M14.83M71.12M52.52M35.76M44.13M35.28M40.59M31.07M19.74M50.02M66.46M73.50M86.25M
Total Liabilities-9.80M34.63M28.25M29.05M27.99M34.52M26.30M25.42M23.80M24.33M39.10M34.86M42.34M42.62M
Total Equity-15.63M-19.80M42.87M23.47M7.77M9.62M8.97M15.17M7.27M-4.58M10.91M31.59M31.15M43.63M
Cash-337.00K7.05M25.42M42.50M28.87M36.07M6.72M7.24M17.38M11.05M33.90M11.87M9.15M4.80M
Total Debt-1.55M------7.49M1.74M1.39M846.00K6.35M6.93M8.15M
Net Debt-1.22M-7.05M-25.42M-42.50M-28.87M-36.07M-6.72M-5.24M-15.63M-9.65M-33.05M-5.52M-2.22M3.35M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.96M-4.73M-9.74M-16.49M-19.60M-16.45M-16.45M-12.15M8.29M-6.89M-8.92M-11.88M-10.46M-13.62M-14.53M
Investing Cash Flow-3.37M-407.00K-2.85M-37.15M36.05M1.82M437.00K-17.04M-6.90M17.39M3.55M-481.00K-34.32M-8.40M-19.54M
Financing Cash Flow7.27M1.77M19.24M72.47M778.00K907.00K23.00M46.00K-1.01M-629.00K-1.05M35.76M22.92M19.39M29.62M
Capital Expenditure849.00K413.00K358.00K396.00K406.00K701.00K1.07M534.00K792.00K923.00K489.00K555.00K6.46M6.27M5.50M
Free Cash Flow-3.81M-5.14M-10.10M-16.89M-20.01M-17.15M-17.53M-12.69M7.50M-7.82M-9.40M-12.44M-16.93M-19.90M-20.04M
FCF to OCF128.68%108.74%103.68%102.40%102.07%104.26%106.53%104.39%90.45%113.39%105.48%104.67%161.77%146.04%137.89%

Earnings

Report DateMay 2, 2014Jul 31, 2014Nov 5, 2014Feb 12, 2015May 4, 2015Aug 3, 2015Oct 27, 2015Jan 25, 2016Apr 21, 2016Jul 28, 2016Nov 14, 2016Feb 21, 2017May 8, 2017Aug 3, 2017Nov 16, 2017Mar 19, 2018May 10, 2018Aug 7, 2018Nov 13, 2018Mar 25, 2019May 21, 2019Aug 12, 2019Nov 14, 2019Feb 25, 2020May 20, 2020Aug 6, 2020Nov 10, 2020Feb 25, 2021May 5, 2021Aug 10, 2021Nov 16, 2021Mar 17, 2022May 17, 2022Aug 9, 2022Nov 15, 2022Mar 16, 2023May 30, 2023Aug 15, 2023Nov 21, 2023Mar 21, 2024May 29, 2024Aug 14, 2024Nov 26, 2024Mar 19, 2025May 21, 2025Aug 14, 2025Nov 20, 2025Mar 5, 2026May 27, 2026Aug 13, 2026Nov 19, 2026
EPS Estimate-1.17-1.37-1.64-1.79-1.76-1.85-2.16-1.63-1.69-1.67-1.80-1.74-1.18-1.37-1.33-1.19-0.94-1.37-1.37-1.06-0.98-0.18-0.91-0.73-1.00-0.84-0.67-0.79-0.81-0.78-0.90-1.05-0.76-0.68-0.68-0.59-0.43-0.34-0.39-0.23-0.41-0.42-0.44-0.59-0.66-0.57-0.83-0.61-0.66-0.76-0.66
EPS Actual-0.35-1.96-1.68-2.29-1.96-1.33-1.19-2.52-1.19-2.38-1.82-0.63-1.40-1.40-1.12-0.63-1.19-1.05-0.77-0.35-1.053.29-0.77-0.91-0.63-0.77-0.49-0.42-0.70-0.84-0.84-1.05-0.84-0.91-0.91-1.18-0.440.10-0.24-0.19-1.05-0.68-0.98-0.36-0.07-1.23-0.24-0.56-0.23-0.77-
Surprise70.09%-43.07%-2.44%-27.93%-11.36%28.11%44.91%-54.60%29.59%-42.52%-1.11%63.79%-18.64%-2.19%15.79%47.06%-26.60%23.36%43.80%66.98%-7.14%1927.78%15.38%-24.66%37.00%8.33%26.87%46.84%13.58%-7.69%6.67%0.00%-10.53%-33.82%-33.82%-100.00%-2.33%129.41%38.46%17.39%-156.10%-61.90%-122.73%38.98%89.39%-115.79%71.08%8.20%65.15%-1.32%-
TimingPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap178.68M
Enterprise Value150.39M
Trailing P/E0.00
Forward P/E34.97
PEG Ratio-0.07
Price / Sales15.06
Price / Book4.97
EPS-2.16
Book Value2.76
Revenue (TTM)11.86M
Gross Profit (TTM)1.83M
EBITDA-30.75M
Profit Margin-170.10%
Operating Margin-305.89%
Return on Equity-72.37%
Return on Assets-28.59%
Shares Outstanding12.91M
Shares Float8.87M
Beta0.14
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 6 analystsTarget 30.67
  • Strong Buy
    4
  • Buy
    2

Ownership Breakdown

Institutions
56.00%
Insiders
16.71%
Retail / Other
27.29%

Top Institutional Holders

  • Investors Finance Co PLC
    872.09K6.75%
  • Yelin Lapidot Holdings Management Ltd
    758.17K5.87%
  • Rosalind Advisors, Inc.
    749.05K5.80%
  • T. Rowe Price Associates, Inc.
    709.85K5.50%
  • BlackRock Inc
    445.83K3.45%
  • Meitav Dash Investments Ltd
    371.87K2.88%
  • Sphera Funds Management Ltd.
    273.19K2.12%
  • Silverberg Bernstein Capital Management LLC
    228.14K1.77%
  • Point72 Asset Management, L.P.
    175.48K1.36%
  • UBS Group AG
    159.79K1.24%
  • State Street Corp
    143.77K1.11%
  • ARK Investment Management LLC
    129.96K1.01%
  • Geode Capital Management, LLC
    121.96K0.94%
  • Northern Trust Corp
    121.78K0.94%
  • Dafna Capital Management LLC
    94.41K0.73%

Top Fund Holders

  • iShares Russell 2000 ETF
    237.03K1.84%
  • T. Rowe Price New Horizons
    233.35K1.81%
  • T. Rowe Price Integrated US Sm Gr Eq
    157.10K1.22%
  • ARK Israel Innovative Technology ETF
    146.72K1.14%
  • Fidelity Small Cap Index
    110.36K0.85%

Stock Splits

  • Dec 20, 20221:7